A clinical trial (ARALAST versus PROLASTIN trial) was conducted to compare the predecessor product ARALAST to a commercially available preparation of Alpha1-PI (PROLASTIN) in 28 subjects with congenital Alpha1-PI deficiency and emphysema, who had not received Alpha1-PI augmentation therapy within the preceding six months.
Subjects were randomized to receive either ARALAST or PROLASTIN, 60 mg/kg intravenously per week for 10 consecutive weeks. Following their first 10 weekly infusions, the subjects who were receiving PROLASTIN were switched to ARALAST while those who already were receiving ARALAST continued to receive it. Table 5 summarizes the mean serum antigenic and functional Alpha1-PI trough levels measured prior to infusion at steady state (Weeks 8 through 11).
Table 5: Steady-State Serum Antigenic and Functional Alpha1-PI Trough Levels Following Intravenous Augmentation Therapy with ARALAST or PROLASTIN | ARALAST Mean ± SD (Range of means) (No. of Subjects = 13) | PROLASTIN Mean ± SD (Range of means) (No. of Subjects = 13) |
|---|
| Antigenic Alpha1-PI | 15.3 ± 2.5 (14.7 to 15.5) microM | 16.9 ± 2.3 (16.2 to 17.2) microM |
| Functional Alpha1-PI | 15.3 ± 2.4 (14.8 to 15.6) microM | 15.7 ± 2.6 (14.4 to 16.4) microM |
Following weekly augmentation therapy with ARALAST or PROLASTIN, a gradual increase in peak and trough serum Alpha1-PI levels was noted, with stabilization after several weeks. The metabolic half-life of ARALAST was 5.9 days. Serum ANEC trough levels rose substantially in all subjects by Week 2, and by Week 3, serum ANEC trough levels exceeded 11 microM in the majority of subjects. With few exceptions, levels in both treatment groups remained above this level in individual subjects for the duration of the period Weeks 3 through 24. Although only five of fourteen subjects (35.7%) receiving ARALAST had BALs meeting acceptance criteria for analysis at both baseline and Week 7, a statistically significant increase in the antigenic level of Alpha1-PI in epithelial lining fluid (ELF) was observed. No statistically significant increase in the ANEC in the ELF was detected.
It was concluded that at a dose of 60 mg/kg administered intravenously once weekly, ARALAST and PROLASTIN had similar effects in maintaining target serum Alpha1-PI trough levels and increasing antigenic levels of Alpha1-PI in the ELF with maintenance augmentation therapy.
The pharmacokinetic comparability of ARALAST NP and the predecessor product ARALAST was demonstrated in a randomized, double-blind, crossover trial in 25 subjects with severe Alpha1-PI deficiency [see Clinical Pharmacology (12.3)].
Another clinical trial (BAL TRIAL) was conducted to determine the effects of open-label, weekly intravenous augmentation therapy with 60 mg/kg ARALAST NP on ELF levels of Alpha1-PI, ANEC, and Alpha1-PI: human neutrophil elastase (HNE) complexes in subjects with severe, congenital Alpha1-PI deficiency. A total of 13 subjects completed 8 weekly infusions of ARALAST NP at a median dose of 63 (range: 58 to 67) mg/kg body weight at an infusion rate of 0.2 mL/kg/min. Of the 13 subjects, 12 had both baseline and post-treatment bronchoalveolar lavage samples. ARALAST NP augmentation therapy resulted in a significant increase (p<0.0001; n=12) in the mean plasma of antigenic Alpha1-PI levels, from a median baseline level of 4.0 (range: 3.1 to 6.3) microM to a median post-treatment level of 14.6 (range: 11.1 to 18.1) microM. Post-treatment values of plasma Alpha1-PI were above 11 microM in all 12 subjects. Median plasma functional Alpha1-PI (ANEC) levels also increased significantly (p<0.0001; n=12) from a median baseline level of 2.5 (range: 1.6 to 3.0) microM to a median post-treatment level of 11.4 (range: 7.8 to 16.9) microM. While antigenic Alpha1-PI levels in the ELF also increased significantly (p=0.0195; n=10) (Figure 3), only 4 out of 12 subjects were observed to have measurable ELF ANEC level in either or both lung lobes following 8 weekly infusions of ARALAST NP and the difference from baseline among these subjects did not reach statistical significance. Changes in the ELF analytes free and total human neutrophil elastase, Alpha1-PI:HNE complexes, IL-8, and TNF alpha were either not statistically significant, or could not be analyzed due to limited data.
Changes in ELF Alpha1-PI (AAT) Levels Following Intravenous Treatment with ARALAST NP (60 mg/kg/week) for 8 Weeks in Subjects with Severe Congenital Alpha1-PI Deficiency
The clinical efficacy of ARALAST NP or any Alpha1-PI product in influencing the clinical course of pulmonary emphysema in Alpha1-PI deficiency has not been conclusively demonstrated in adequately powered, randomized, controlled clinical trials.